Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases

NCT07745257 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

HR-positive, HER2-negative Metastatic Breast Cancer With Brain Metastases

Interventions

DRUG: Culmerciclib
DRUG: Anlotinib
DRUG: Endocrine Therapy

Sponsor

Sun Yat-sen University